Tower Research Capital (TRC)’s Gyre Therapeutics GYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $40.2K | Buy |
5,763
+3,686
| +177% | +$28.6K | ﹤0.01% | 2942 |
|
|
2025
Q4 | $14.7K | Sell |
2,077
-617
| -23% | -$4.76K | ﹤0.01% | 3341 |
|
|
2025
Q3 | $20.1K | Buy |
2,694
+570
| +27% | +$4.33K | ﹤0.01% | 3305 |
|
|
2025
Q2 | $15.6K | Buy |
2,124
+1,075
| +102% | +$9.38K | ﹤0.01% | 3808 |
|
|
2025
Q1 | $8.1K | Buy |
1,049
+197
| +23% | +$2.16K | ﹤0.01% | 3917 |
|
|
2024
Q4 | $10.3K | Sell |
852
-6
| -0.7% | -$77 | ﹤0.01% | 3814 |
|
|
2024
Q3 | $10.8K | Buy |
858
+609
| +245% | +$7.85K | ﹤0.01% | 3721 |
|
|
2024
Q2 | $2.97K | Sell |
249
-2,603
| -91% | -$35.7K | ﹤0.01% | 4944 |
|
|
2024
Q1 | $49.9K | Buy |
2,852
+2,186
| +328% | +$39.4K | ﹤0.01% | 2275 |
|
|
2023
Q4 | $17.1K | Buy |
666
+398
| +149% | +$5.65K | ﹤0.01% | 3749 |
|
|
2023
Q3 | $1.94K | Buy |
268
+182
| +212% | +$1.22K | ﹤0.01% | 5237 |
|
|
2023
Q2 | $452 | Sell |
86
-6
| -7% | -$22 | ﹤0.01% | 5640 |
|
|
2023
Q1 | $0 | Sell |
92
-94
| -51% | -$357 | ﹤0.01% | 6004 |
|
|
2022
Q4 | $1K | Sell |
186
-91
| -33% | -$371 | ﹤0.01% | 5604 |
|
|
2022
Q3 | $1K | Buy |
277
+119
| +75% | +$1.51K | ﹤0.01% | 5786 |
|
|
2022
Q2 | $2K | Sell |
158
-265
| -63% | -$1.76K | ﹤0.01% | 5546 |
|
|
2022
Q1 | $2K | Buy |
+423
| New | +$2.1K | ﹤0.01% | 5554 |
|
|
2021
Q2 | – | Sell |
-366
| Closed | -$14K | – | 5618 |
|
|
2021
Q1 | $14K | Buy |
366
+68
| +23% | +$3.11K | ﹤0.01% | 4148 |
|
|
2020
Q4 | $14K | Sell |
298
-2,145
| -88% | -$92.9K | ﹤0.01% | 4092 |
|
|
2020
Q3 | $79K | Buy |
2,443
+933
| +62% | +$36.5K | ﹤0.01% | 3316 |
|
|
2020
Q2 | $66K | Buy |
1,510
+1,290
| +586% | +$60.6K | ﹤0.01% | 2830 |
|
|
2020
Q1 | $8K | Sell |
220
-138
| -39% | -$6.34K | ﹤0.01% | 2119 |
|
|
2019
Q4 | $18K | Buy |
358
+347
| +3,155% | +$14.5K | ﹤0.01% | 1990 |
|
|
2019
Q3 | $0 | Sell |
11
-527
| -98% | -$28.4K | ﹤0.01% | 4257 |
|
|
2019
Q2 | $29K | Buy |
538
+515
| +2,239% | +$32.2K | ﹤0.01% | 1926 |
|
|
2019
Q1 | $1K | Buy |
+23
| New | +$1.48K | ﹤0.01% | 3564 |
|
|
2018
Q4 | – | Sell |
-124
| Closed | -$10K | – | 4025 |
|
|
2018
Q3 | $10K | Buy |
124
+74
| +148% | +$5.86K | ﹤0.01% | 2756 |
|
|
2018
Q2 | $4K | Buy |
+50
| New | +$8.77K | ﹤0.01% | 3132 |
|
|
2016
Q3 | – | Sell |
-4
| Closed | -$1K | – | 3948 |
|
|
2016
Q2 | $1K | Buy |
+4
| New | +$682 | ﹤0.01% | 4155 |
|
|
2016
Q1 | – | Sell |
-5
| Closed | -$1.21K | – | 4448 |
|
|
2015
Q4 | $2K | Sell |
5
-13
| -72% | -$5.11K | ﹤0.01% | 3735 |
|
|
2015
Q3 | $9K | Buy |
+18
| New | +$27.4K | ﹤0.01% | 2386 |
|
|
2014
Q2 | – | Sell |
-3
| Closed | -$13K | – | 4278 |
|
|
2014
Q1 | $13K | Buy |
+3
| New | +$11.1K | ﹤0.01% | 2341 |
|
|
2013
Q4 | – | Sell |
-1
| Closed | -$5K | – | 4649 |
|
|
2013
Q3 | $5K | Sell |
1
-5
| -83% | -$20.1K | ﹤0.01% | 3651 |
|
|
2013
Q2 | $19K | Buy |
+6
| New | +$22.8K | ﹤0.01% | 1762 |
|
Other funds holding GYRE
VCM
SS
VFT
VPM
Tower Research Capital (TRC)'s GYRE Position: Q1 2026 in Review
Tower Research Capital (TRC) increased its Gyre Therapeutics (GYRE) stake by 177% in Q1 2026, buying an estimated $28.6K and bringing the position to 5,763 shares worth $40.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2942.
Tower Research Capital (TRC) first reported a position in GYRE in Q2 2013 and has held it in 34 quarters since. The position peaked at $79K in Q3 2020. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.
- Tower Research Capital (TRC) held 5,763 shares of Gyre Therapeutics worth $40.2K as of Q1 2026.
- Tower Research Capital (TRC) bought 3,686 Gyre Therapeutics shares in Q1 2026, an estimated $28.6K.
- Gyre Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2942 holding.
- Tower Research Capital (TRC) first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 34 quarters since.
- Tower Research Capital (TRC)'s Gyre Therapeutics position peaked at $79K in Q3 2020.
- 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.